Telix Pharmaceuticals upsizes convertible bond offering to $600m
Telix Pharmaceuticals has upsized its convertible bond offering to $600m after strong institutional demand, pricing the five-year notes at a 1.5% coupon to fund a major repurchase of its existing 2029 paper.
Australian biopharmaceutical company Telix Pharmaceuticals has successfully priced an upsized $600 million convertible bond offering through its US subsidiary, increasing the deal from an initial $550 million target.
Sign in to read on!
Registered users get 2 free articles in 30 days.
Subscribers have full unlimited access to CorporateTreasurer.
Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.
If you are a treasurer, CFO or senior financial professional at a corporate or SME, please register for free VIP access here.
Questions?
See here for more information on licences and prices, or contact [email protected].
© Haymarket Media Limited. All rights reserved.
Top news, insights and analysis every Tuesday & Thursday
Free registration gives you access to our email newsletters
for unlimited access to all articles, newsletters
